Interview with Howard Balloch, President, The Balloch Group
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 41 member companies with pharmaceutical R&D capability.
Statistics show that over RMB20 billion was invested by 40 RDPAC members during the 11th Five Years Plan. And nearly one-third of the investment was allocated in the construction of R&D centre. 70% of RDPAC members have established manufacturing facilities in China summing up to 49 in total so far, and 31 R&D centres were established by 17 companies.
Holding the idea of “Healthier China through Innovation”, RDPAC committed to being a valued partner in delivering the “Healthy China 2020” goal to improve the health and quality of life of people in China：
● Providing our high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
● Committed to securing patients timely access to innovative & high quality drugs;
● Achieving highest standard of integrity for ethical research and business practice;
● Contributing to the growth of the biopharmaceutical sector in China;
● Supporting the development of a sustainable healthcare system in China.
RDPAC is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Contact
Rm 506, Office Bldg 1, Landmark Tower, No.8 North Dongsanhuan Rd, Chaoyang District, Beijing 100004, P.R.China
Tel: +86 10 6590 7696
info@rdpac.org
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
You have had significant experience at GSK and Pfizer, and also at Frontage Labs doing more entrepreneurial work. What ultimately brought you to Covance? I worked in Big Pharma for…
Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations, making it more convenient…
Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you…
In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re…
What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the late 1980s that there…
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps…
Could you please give a brief introduction to the ABO and its history? ABO was established in 2005. The CRO business emerged in 2000 in China, and provided services for…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group. Could you highlight the…
You have been here in China for about a year. What were your assumptions about China before you arrived and were things more or less what you thought they would…
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
See our Cookie Privacy Policy Here
